Ideaya pushes on with a dual ADC approach

Less than four months after striking a deal with Biocytogen covering B7-H3/PTK7 dual targeting ADCs Ideaya Biosciences has exercised its option on one such project, now codenamed IDE034. The agreement throws a spotlight on PTK7, also a key focus for Kelun, and where Lilly recently unveiled its ADC LY4175408, preclinical data on which featured at the Triple meeting in October. However, IDE034 is the only asset in development hitting both PTK7 and B7-H3, according to OncologyPipeline. B7-H3 is a popular target for small-cell lung cancer, with Merck & Co and GSK both striking deals last year, for Daiichi’s ifinatamab deruxtecan and Hansoh’s HS-20093 (now GSK5764227) respectively. According to Ideaya, PTK7 and B7-H3 are co-expressed in lung, colorectal, and head and neck cancers at around 30%, 46% and 27% respectively. Biocytogen also has a couple more dual PTK7 projects, while other approaches include radioconjugates and Car-T. Ideaya plans an IND filing next year for IDE034, which uses a topoisomerase inhibitor payload. In this way it’s similar to Lilly’s PTK7 newcomer LY4175408, Kelun’s SKB518 and Day One/MabCare’s DAY301; however, the most advanced PTK7 ADC, Genmab’s GEN1107, uses an MMAE payload, as did Pfizer and AbbVie’s cofetuzumab pelidotin, discontinued last year.

The PTK7 pipeline

Source: OncologyPipeline.